Pharma News

 

Clinical courses

 

Clinical research courses

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • Breakthrough research makes cancer-fighting viral agent more effective
    1 July 2024

    Breakthrough research makes cancer-fighting viral agent more effective

    Researchers from Aarhus University have made a significant breakthrough by discovering that the drug 4-OI can enhance the effectiveness of a cancer-fighting viral agent. This may lead to treatment of cancers that are otherwise resistant to therapies.
  • 1 July 2024
    Study reveals why AI models that analyze medical images can be biased
    Artificial intelligence models often play a role in medical diagnoses, especially when it comes to analyzing images such as X-rays. However, studies have found that these models don’t always perform well across all demographic groups, usually faring worse on women and people of color.
  • 1 July 2024
    Cosmohome Tech Expo 2024

    Cosmohome Tech Expo was held in Delhi at Pragati Maidan from 26th to27st June 2024. It was its 10th edition, comprising of more than 350 Exhibitors who displayed  latest Ingredients, Formulations, Fragrances, Packaging, Instruments, Machinery, Labelling and Contract Manufacturing.

  • 27 June 2024
    New Approach Accurately Identifies Medications Most Toxic to the Liver
    The current method for assessing medication-related liver injury is not providing an accurate picture of some medications toxicity or lack thereof to the liver, according to a new study led by researchers from the Perelman School of Medicine at the University of Pennsylvania. Classification of a medication’s potential to damage the liver, termed hepatotoxicity, has been historically determined by counting individual reported cases of acute liver injury
  • 27 June 2024
    New study demonstrates the efficacy of a promising celiac disease drug at the molecular level

    A recent study led by researchers at Tampere University investigated whether a transglutaminase 2 inhibitor has potential as a drug to treat celiac disease. Previous tissue studies have shown that the ZED1227 transglutaminase 2 inhibitor prevents gluten-induced intestinal damage. The results of the new study, based on an analysis of the molecular activity of more than 10,000 genes, provide very strong evidence that the first successful drug to treat celiac disease may be at hand.

  • 26 June 2024
    Novo Nordisk announces 4.1 billion USD investment to expand US manufacturing capacity
    Novo Nordisk today announced plans to invest 4.1 billion US dollars (approx 27 billion Danish kroner) to build a second fill and finishing manufacturing facility in Clayton, North Carolina, and grow its ability to produce current and future injectable treatments for people with obesity and other serious chronic diseases.
  • 26 June 2024
    USDA approves Merck Animal Health’s NOBIVAC NXT Canine Flu H3N2
    NOBIVAC NXT is a revolutionary, first-of-its-kind vaccine technology for companion animals that leverages RNA-particle technology, allowing for a precise immune response to protect against a wide range of viral and bacterial pathogens.
  • 25 June 2024
    EMA approves Biocon Biologics’ New mAbs Facility in India and Renews GMP Certifications for India and Malaysia Sites
    Biocon Biologics Ltd , a global, fully integrated biosimilars company and a subsidiary of Biocon Ltd, has received approval from the European Medicines Agency to manufacture biosimilar Bevacizumab at its new, world-class, multi-product monoclonal antibodies mAbs drug substance facility at Bengaluru.
  • 25 June 2024
    US lawmakers probe USFDAs inspection in India and China
    US lawmakers probe USFDAs inspection in India and China where they found many variations in inspection outcomes. In a new letter to Food and Drug Administration (FDA) Commissioner Robert Califf, House Energy and Commerce Committee Chair Cathy McMorris Rodgers, Subcommittee on Health Chair Brett Guthrie, and Subcommittee on Oversight and Investigations Chair Morgan Griffith are pressing for more information regarding the agency’s foreign drug inspection program.
  • 18 June 2024
    FDA grants accelerated approval to repotrectinib for adult and pediatric patients with NTRK gene fusion-positive solid tumors

    The Food and Drug Administration granted accelerated approval to repotrectinib (AUGTYRO, Bristol-Myers Squibb Company) for adult and pediatric patients 12 years and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, are locally advanced or metastatic or where surgical resection is likely to result in severe morbidity, and that have progressed following treatment or have no satisfactory alternative therapy.

Subscribe to Pharma News

Subscribe with us




 


 

 

Do Not Forget to Verify

(Click on Subscription link in your inbox)

--------

whatsapp

 

Also Join:  youtube  telegram

admission for pharma MBA

 

admission for pharma MBA

Jobs by Category

Production Jobs

R&D Jobs

F&D Jobs

Sales & Marketing

QA Jobs

QC Jobs

Faculty Jobs

CRO Jobs

DRA Jobs

IPR Jobs

IT Jobs

Packaging Alerts

Hospital Pharmacist